Longevity-Focused Wellness Expo to Debut in West Palm Beach
WEST PALM BEACH, FLORIDA / ACCESS Newswire / May 12, 2025 / Be part of the longevity medicine revolution! Tickets are on sale for The Longevity Expo, a new, two-day wellness event coming to the West Palm Beach Convention Center, Saturday and Sunday, May 31 and June 1. Chaired and hosted by renowned author, Sara Gottfried, M.D., this event aims to equip guests with insights and tools to boost their well-being and embrace a longer, healthier life.Dr. Sara Gottfried The New York Times bestselling author and scientist, Dr. Sara Gottfried, will host the upcoming Longevity Expo in West Palm Beach.
Produced by Informa Connect, the event will highlight the newest advancements in longevity medicine, offering panels, fireside chats, and breakout sessions led by leading experts in wellness medicine. Attendees can explore interactive halls filled with cutting-edge technologies and observe live demos, as well as unwind in outdoor lounges featuring food and music for an elevated Palm Beach atmosphere.
'Longevity medicine is no longer science fiction, it's a revolution,' said Dr. Sara Gottfried. 'In a fast-paced world, society demands high performance at every age, and we finally have the tools to deliver it.'
A soon-to-announced New York Times best selling author, entrepreneur, and philanthropist will headline the event as keynote speaker, setting the tone for an impactful and informative experience. Over the course of two days, the expo will feature 11 speakers, ranging from celebrity fitness trainers to award-winning authors, nutrition experts, and physicians. Notable speakers include Judith Joseph, M.D., American physician and author; Michael Greger, M.D., American physician, speaker, and author; Erica Lugo, former trainer on USA Network's The Biggest Loser and women's wellness expert; and JJ Virgin, celebrity nutrition and fitness expert, as well as CEO and founder of the Everyday Wellness Project, among others.
Topics will cover an array of subjects such as hormones, weight management, brain health, mental wellness, fitness, sleep, intimacy, and more. Join in on spotlight discussions tailored to be energizing and inspiring, with fun takes on wellness topics such as, 'Why Do I Have So Much Rage?' and 'Sex, Drugs, and Rock and Roll.'
'We're creating an electric atmosphere to educate, inspire, and give real-life solutions,' Dr. Gottfried continued. 'The boom in longevity medicine reflects a new shift from not just treating an illness, but to optimizing life. Prevention is the new power.'
Explore the show's expo hall to see the latest innovations in longevity, biohacking, fitness, and functional medicine. Join cryotherapy sessions and yoga classes or try red light therapy and wearable tech. The expo blends education with an elevated lifestyle experience.
The Longevity Expo offers several ticket options for purchase, including VIP Longevity Experiences, two-day passes, and one-day passes. These tickets provide varying levels of access, from exclusive perks, such as entry to a VIP lounge and networking receptions, to general access to keynote sessions, the expo hall, the full agenda, and attendee gift bags.
For more information about The Longevity Expo, to view the full schedule, and to purchase tickets, visit thelongevityexpo.com.
Contact Information
Chelsea Casagrande
Director of Public Relations
[email protected]
(561) 844-1778, ext. 120
SOURCE: Venue Marketing Group
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
27 minutes ago
- Medscape
Implantable Device Shows Promise for Preventing Hypoglycemia
A new minimally invasive device, while still in development, could become a lifesaver for individuals with diabetes who experience hypoglycemia, according to researchers at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts. In a paper published in Nature Biomedical Engineering , Siddharth R. Krishnan, PhD, now an assistant professor of electrical engineering at Stanford University in Stanford, California, and colleagues at MIT described a wireless device implanted into diabetic mice that prevented hypoglycemia. The implant weighs < 2 g and is only 3 cm3 in size; it remains under the skin and releases a powdered version of glucagon automatically when a sensor detects low blood sugar. The researchers simulated hypoglycemia in the mice, and the release of the dry glucagon was triggered wirelessly. Measurements showed a rapid rise in blood glucose soon after the release, with a peak of 30 mg/dL after no more than 15 minutes. A second set of studies replicated conditions that often drive hypoglycemia, such as missed meals and automated infusions from insulin pumps. Similarly, the use of the wireless release of dry glucagon resulted in blood glucose concentrations above the threshold for hypoglycemia (average concentration of 80 mg/dL) within the first hour after the release. An area under the curve analysis over 30 minutes after release showed significant changes in the glucose group compared with the control group who received lactose. 'A Pathway to Emergency Rescue' 'Glucagon is widely administered as an emergency rescue drug for patients suffering acute hypoglycemia, particularly in the context of type 1 diabetes,' corresponding author Daniel Anderson, PhD, a professor at the Koch Institute for Integrative Cancer Research at MIT, told Medscape Medical News . Glucagon's short half-life and low stability in solution has made development of pump systems a challenge, he said. By contrast, 'Dry powder versions of glucagon offer long-term stability but are difficult to deliver,' he said. 'An implantable device that can respond to hypoglycemia and release dry powder glucagon potentially offers a pathway to emergency rescue from hypoglycemia events without the need for patient intervention,' Anderson said. The early impact of the dry power was unexpected, Anderson said. 'The glucagon in our system is a dry powder that we designed to dissolve directly in biofluid, and the timeline for this dissolution and subsequent availability of the drug in circulation was an open question when we started this project,' he noted. 'The fact that we saw biological activity within 5 minutes of drug release was an important result in this context, and not one that we predicted.' Although the device is not ready for human use, the size and longevity are key questions for adoption in clinical practice, Anderson told Medscape Medical News . 'We are working on miniaturizing the device, so it is compatible with minimally invasive insertion techniques, and with a sufficient number of doses to provide protection from acute hypoglycemia for multiple years,' he said. 'So far, we have validated the device in preclinical small animal models.' Simultaneously miniaturizing the system and optimizing the dose and longevity in large animal models are the next steps for research, he added. Unmet Need for Glycemic Control 'Hypoglycemia and fear of hypoglycemia remains major barriers to optimal glycemic control for those with diabetes,' said Andrew Kraftson, MD, a specialist in endocrinology and internal medicine at the University of Michigan, Ann Arbor, Michigan, in an interview. 'Glucagon emergency delivery devices have advanced and become more user friendly but will not work if not available or expired. Liquid glucagon presents numerous challenges and is not yet commercially available for dual hormone insulin pump use,' said Kraftson, who was not involved in the research. 'Dual hormone pumps that are being studied or have been approved in Europe are large/bulky, may require two CGM [continuous glucose monitoring] sensors, and may require glucagon to be refilled more frequently than insulin, so a nonliquid, implantable device could avoid some of the obstacles posed by liquid glucagon,' Kraftson noted. However, more research is needed on the logistics of human implementation of the glucagon delivery device tested in the current study, Kraftson told Medscape Medical News . Questions include how the device would be implanted; how many doses the reservoir would hold; and how often, on average, it would need to be changed, he said. Other factors include how cumbersome this device might be for humans, potential risks for irritation or infection, and options for manual delivery in the event of a malfunctioning CGM or signal challenges in device communication, he said. 'Ideally, glucagon use for patients with diabetes would expand beyond emergency rescue,' Kraftson added. 'Reducing or even holding insulin is sometimes insufficient to avoid hypoglycemia, particularly rapid onset.' 'Additionally, eating carbohydrates to prevent or treat hypoglycemia is not ideal given the risk of subsequent overcorrection/hyperglycemia and weight gain; therefore, more frequent, sensor/algorithm-based use of glucagon can more effectively achieve stable glucose levels and help avoid the 'rollercoaster,'' he said. The small size of the device in the current study may limit its ability to participate in the larger mission of glucose management but could certainly still play an important role in hypoglycemia reduction, he noted. This study was funded by the Leona M. and Harry B. Helmsley Charitable Trust, the National Institutes of Health, a JDRF postdoctoral fellowship, and the National Institute of Biomedical Imaging and Bioengineering. Anderson and several coauthors reported being inventors on a patent application relevant to the technology described in this study but had no other financial conflicts of interest.
Medscape
27 minutes ago
- Medscape
Canada Issues Sweeping Updates for Obesity Pharmacotherapy
TOPLINE: Canada has released an updated guideline on pharmacotherapy for obesity management in adults that includes six new and seven revised recommendations, reflecting the latest evidence through May 2025. METHODOLOGY: Researchers conducted a systematic literature review from January 2022 to July 2024, supplemented by relevant trials published through May 2025, to identify studies assessing the efficacy of pharmacotherapy for weight management. They also conducted 13 targeted searches on managing weight-related complications in 13 subpopulations with adiposity-related health issues, including cardiovascular disease, heart failure, prediabetes, obstructive sleep apnea, and osteoarthritis, among others. Primary care physicians, obesity medicine specialists, and people with lived experience of obesity provided feedback on the recommendations. TAKEAWAY: Measures of central adiposity, in addition to ethnicity-specific BMI and adiposity-related complications, should be used to guide the decision to initiate pharmacotherapy. Obesity pharmacotherapy should be used in conjunction with health behavior changes and individualized based on a person's specific health needs, values, and preferences. The recommendations include two new medications, tirzepatide and setmelanotide, that were not included in previous versions of the guideline, as well as new recommendations for obesity-related complications. The researchers recommend against the use of compounded medications or medications other than those approved for weight loss in people with excess adiposity. IN PRACTICE: Obesity pharmacotherapy 'is one of three pillars of treatment outlined in the full Canadian Adult Obesity Clinical Practice Guideline, with other pillars being behavioral and psychological and surgical approaches,' said the author in a press release. 'Obesity treatment should always be tailored to each person's specific health needs, values, and preferences.' SOURCE: The study, led by Sue Pedersen, MD, endocrinologist and obesity medicine specialist in Calgary and lead author of the guideline, was published online in the Canadian Medical Association Journal. LIMITATIONS: The guideline has limitations, in that it includes only medications currently approved in Canada, although other medications are approved for obesity management in other countries. Also, there are more than 200 health complications associated with obesity, and it was not feasible to search the literature for all of them. DISCLOSURES: Pedersen reported receiving grants for clinical trials from Novo Nordisk, AstraZeneca, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Prometric, and Pfizer, and consulting fees from AstraZeneca, Bausch Health, Eli Lilly and Company, Novo Nordisk, Janssen, Boehringer Ingelheim, Sanofi, Merck, Abbott, Dexcom, HLS, Bayer, AbbVie, Roche, Amgen, and Pfizer. She has also received payment for medical education lectures and speakers bureaus from AstraZeneca, Bausch, Eli Lilly and Company, Novo Nordisk, Janssen Pharmaceuticals, Boehringer Ingelheim, Sanofi, Merck, Abbott, Dexcom, HLS, Bayer, and Pfizer, and has received travel support from AstraZeneca, Bausch, Eli Lilly and Company, Novo Nordisk, Boehringer Ingelheim, Abbott, and Dexcom. In addition, Pedersen reported participating on a data safety monitoring board for Regeneron. The other coauthors also report receiving fees from multiple commercial entities. These competing interests are included in the paper. Marilynn Larkin, MA, is an award-winning medical writer and editor whose work has appeared in numerous publications, including Medscape Medical News and its sister publication MDedge, The Lancet (where she was a contributing editor), and Reuters Health. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Associated Press
28 minutes ago
- Associated Press
Former K-9 Maple is busy as a bee sniffing out threats to Michigan State University colonies
EAST LANSING, Mich. (AP) — Researchers at a Michigan State University facility dedicated to protecting honey bees are enlisting a four-legged ally to sniff out danger to the prized pollinators. The Pollinator Performance Center's wide range of projects includes developing a training program for dogs to use their sensitive noses to uncover a bacterial disease called American foulbrood that threatens honey bee larvae. Bees and other pollinators have been declining for years because of disease, insecticides, climate change and lack of a diverse food supply. A considerable portion of the human diet comes from plants pollinated by bees. Maple, who once served as a human remains detection dog for the St. Joseph County sheriff's office, has created quite the buzz. The panting 9-year-old English springer spaniel stood patiently on a recent weekday as Sue Stejskal, her longtime owner, trainer and handler, slowly placed the retired K-9 in a yellow protective suit. The garment includes a veil for her head and four booties worn on her paws in case Maple steps on a bee. 'Much like with humans, we recognize that if a dog is going to be in an active bee yard, they need to wear the same personal protective equipment as people do,' said Stejskal, a Michigan State graduate who has been training dogs over a quarter-century for law enforcement and other uses. 'You can't buy them on Amazon for dogs. So, there's been some altering and testing.' Maple suffered an injury while on a case in Ontario, forcing her to retire as a detection K-9 in 2024. But fate intervened. Meghan Milbrath, an MSU professor whose lab studies risk factors that affect honey bees' health, was working to establish diagnostic and screening tools for honey bee diseases. A veterinarian who participated in a training about honey bees put Milbrath in touch with Stejskal. They met, and the dog detection plan was born. Stejskal then set about teaching an old dog a new trick. New to Maple, anyway. Maryland's agriculture department has also used canine detection methods in beehives. Michigan State's objective is to train many more dogs to join the ranks. Milbrath said she is documenting Maple's training and plans to write a book with Stejskal to educate other teams about their strategy. Maple, clad in her yellow suit, raced between hive boxes during a recent demonstration. When she found the scent clue left for her, Maple stopped at the box and coolly looked up at Stejskal. 'Good girl. Yes,' Stejskal enthusiastically said, before removing Maple's veil and tossing a green, Michigan State-branded toy her way. Stejskal recognizes the work they're doing is important. 'It's a cool project,' Stejskal said. 'But I was over-the-moon excited, because my dog would still have joy in her life and would still be able to work.'
